SAN JOSE, Calif.--(BUSINESS WIRE)--Chronix Biomedical today announced that it will launch a new disease detection and monitoring service for cancer researchers at the upcoming 2010 ASCO Annual Meeting. The “For Investigational Use Only” laboratory-based testing service uses Chronix’s breakthrough approach—the Chronix Apoptotic DNA Blood Test—which analyzes apoptotic DNA from dead and dying cells to identify and track ongoing changes associated with specific cancers and other chronic diseases. Chronix’s proprietary blood test has been shown to accurately detect disease much sooner than other testing methodologies. The Chronix test also reports information that may have utility for selecting the best treatment for each patient. The new service will initially be offered to cancer researchers in the medical oncology and pharmaceutical research communities.
